Who is sponsoring NCT00919269?

NCT00919269 is sponsored by Children's Oncology Group.

What drugs are being tested in NCT00919269?

Interventions in NCT00919269: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis.

What condition does NCT00919269 study?

NCT00919269 studies Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Chordoma, Desmoid-Type Fibromatosis, Metastatic Childhood Soft Tissue Sarcoma, Non-Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7, Untreated Childhood Rhabdomyosarcoma.

Is NCT00919269 still recruiting?

NCT00919269 is currently completed. Last updated 3 October 2023.

Last reviewed 2023-10-03 · How we verify

NCT00919269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Completed Last updated 3 October 2023

What this trial tests

trial testing Cytology Specimen Collection Procedure in Adult Rhabdomyosarcoma in 150 participants. Completed in 30 September 2023.

Timeline

15 March 1999

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Children's Oncology Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	15 March 1999
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	247 locations across New Zealand, Netherlands, Canada, Puerto Rico, Australia, Switzerland, United States

Drugs / interventions tested

Cytology Specimen Collection Procedure
Laboratory Biomarker Analysis — full drug profile →

Conditions studied

Adult Rhabdomyosarcoma — all drugs for Adult Rhabdomyosarcoma →
Childhood Desmoplastic Small Round Cell Tumor — all drugs for Childhood Desmoplastic Small Round Cell Tumor →
Chordoma — all drugs for Chordoma →
Desmoid-Type Fibromatosis — all drugs for Desmoid-Type Fibromatosis →

Sponsor

Children's Oncology Group — full company profile →

Who can join

Under 50, any sex, with Adult Rhabdomyosarcoma or Childhood Desmoplastic Small Round Cell Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test in the laboratory may help the study of cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma.
Kim J, Light N, Subasri V, Young EL, et al · · 2021 · cited 36× · PMID 34095712 · DOI 10.1200/po.20.00218

Verify or expand the search:

Other trials of Cytology Specimen Collection Procedure

Trials testing the same drug.

NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04526587 — Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors · recruiting
NCT02514408 — Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer · withdrawn
NCT03057626 — Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma · active not recruiting

Other Children's Oncology Group trials

Trials by the same sponsor.

NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00919269 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 3 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00919269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing